Biotech China 2014

Cell Biology: Bristol-Myers Squibb

Total Score People Score Events Score
18 16 16
Date Event Presentation Speakers
November 12, 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Development of ipilimumab (anti-CTLA-4) and beyond: Contribution to a new immunotherapy paradigm Axel Hoos
April 11, 2011 Personalized Medicine Partnerships Conference Rx/Dx Partnering | Two Products Towards One Goal | Delivering the Prospect of Personalized Medicine Andrea H. Lauber
August 25, 2010 Co-Development of Drugs and Diagnostics Challenges of Co-Development of Therapeutics and Companion Diagnostics Andrea H. Lauber
July 7, 2010 WIN Symposium in personalized cancer medicine Phase II and III clinical trial design and endpoints in targeted therapy era-future goals and challenges. Giuseppe Giaccone
June 10, 2009 Second Annual Hepatotoxicity and Drug Safety The Challenges of Predicting Metabolism-Mediated Toxicity In Vitro Frederic Moulin
June 9, 2009 RNAi for Target Identification and Validation Use of RNAi Screens with Physiologically Relevant Cell Models to Identify Novel Therapeutic Targets Namjin Chung
February 23, 2009 Advances and Progress in Drug Design VIII p38 MAP KINASE INHIBITORS: A CASE STUDY IN STRUCTURE-BASED DRUG DESIGN Arthur M Doweyko
January 27, 2009 4th Annual Aseptic Filling and Processing ICH Q8. Q9 & Q10: A one stop and critical update on the aspects you should be aware of Barbara Sambuco
May 30, 2008 ASCO Annual'08 Meeting clinical trials-- Choice of Comparator in Pivotal Phase III Clinical Trials: Clinical Versus Regulatory Standard of Care Steven D. Averbuch
clinical trials-- Endpoints for Immunotherapy Studies: Design and Regulatory Implications Axel Hoos
international-- Choice of Comparator in Pivotal Phase III Clinical Trials: Clinical Versus Regulatory Standard of Care Steven D. Averbuch
tumor biology-- Endpoints for Immunotherapy Studies: Design and Regulatory Implications Axel Hoos
March 25, 2008 Molecular Diagnostics Affordability Through Sustainability – A New Approach to Technology Innovation Balu Balasubramanian
March 25, 2008 R&D Risk Mitigation Alliance Management: How Can Large and Small Companies Work Together? Teresa Faria
December 1, 2007 47TH American Socieity of Cell Biology Post-Cytokinetic DNA Segregation by ATPases That Form DNA-Conducting Channels Lois Burton
October 17, 2007 Inaugral Nuclear Harmone Receptors Modulators: Targets for Drug Discovery Oct (17-18) DISCOVERY CHEMISTRY (08:35-12:55) Lawrence G. Hamann
DISCOVERY CHEMISTRY: Tissue Selective Androgen Receptor Modulators (11:25-11:55) Lawrence G. Hamann
October 16, 2007 Fifth Annual RNAi for Drug Discovery and Therapeutics - Best Practices from the Bench to the Clinic Oct (16-17) RNAi FOR IN VIVO TARGET VALIDATION: Validation of Drug Targets Through in vivo Application of siRNA Oligonucleotides (16:30-17:00) Siew Ho
RNAi FOR IN VIVO TARGET VALIDATION (16:30-19:30) Siew Ho
October 11, 2007 Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12) SELECTING LEADS AND DETECTING ADVERSE ACTIVITY: Characterizing the Multiple Activities of Kinase Inhibitors (15:05-15:35) Petra Ross-Macdonald
SELECTING LEADS AND DETECTING ADVERSE ACTIVITY (14:00-17:30) Petra Ross-Macdonald
September 17, 2007 Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19) Third annual Genomic Biomarkers: PHARMACOGENETICS: Changing the Benefit/Risk Profile Using Pharmacogenetics (09:05-09:35) Koustubh Ranade
Third annual Genomic Biomarkers: PHARMACOGENETICS (08:30-11:30) Koustubh Ranade
Third annual Genomic Biomarkers: VALIDATION OF GENOMIC BIOMARKERS: Discovery and Validation of Biomarkers Affected by Brivanib and Erbitux (11:30-12:00) J. Suso Platero
Third annual Genomic Biomarkers: VALIDATION OF GENOMIC BIOMARKERS (11:30-14:00) J. Suso Platero
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.